In this year's CIIE Medical Devices and Healthcare Exhibition Area, the world's top 15 pharmaceutical giants gathered at the Expo for the first time in five years, demonstrating the confidence of multinational pharmaceutical companies in the Chinese market. Many companies have placed their world premiere and China premiere at the Expo.
And how to land the global new drugs that Chinese patients care about as soon as possible has also handed over the "answer sheet" on the stage of the Expo: due to the strong "spillover effect" of the Expo, exhibitors who exhibit every year have exhibits turned into commodities every year, from the first exhibition to the first prescription for patients!
From China speed to China breadth
Dapitto appeared in the Expo five times
Revolutionary therapies reach the entire population
The new indication for moderate to severe atopic dermatitis (AD) star product of type 2 inflammation-driven atopic dermatitis (AD) from 6 months to 5 years old was newly unveiled at Sanofi's booth this year, and this new indication has been accepted for marketing application by the Drug Evaluation Center of the National Medical Products Administration. Thanks to the "spillover effect" of the Expo, Dapitou went to the Expo five times, which not only opened the "China speed" all the way, but also expected to achieve the "China breadth" of benefits for people of all ages, help the whole population of patients achieve the long-term disease control goal, and improve the quality of life.
As one of the most prevalent skin diseases of all ages, atopic dermatitis is known as the "number one disease" of dermatology and the first disease burden among non-fatal skin diseases.
The reporter learned from the booth that after the debut of Dabito at the first CIIE in 2018, every step from approval, listing to medical insurance landing reflects the "China speed" of accelerating the accessibility of innovative drugs, and witnesses specific examples of China accelerating the introduction of breakthrough innovative drugs to meet urgent clinical needs.
With the 5 years of CIIE, Dapitto has continuously expanded its indications, and now covers adults, adolescents, children and other patients with moderate to severe atopic dermatitis in China. This year, the FDA approved d'abilal for patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years who can't be treated or controlled with topical therapies, which means that d'atopic dermatitis is currently the only systemic treatment for atopic dermatitis covering the entire population, from infants to adults.
Xie Lijuan, General Manager of Sanofel Pharmaceuticals Global Business Unit China, said: "As a multinational pharmaceutical company that has actively participated in CIIE for five consecutive years, we are fortunate to witness the Chinese government's strong promotion of medical innovation, and also benefit from the strong 'spillover effect' of CIIE, Dapitol continues to expand new indications, accelerating 'China speed, China breadth, and Chinese temperature' to benefit Chinese patients of all ages. ”
The reporter learned that in order to promote the standardized management of online diagnosis and treatment of atopic dermatitis, at this year's Expo, Sanofi announced that the strategic cooperation with JD Health in the field of digital intelligent diagnosis and treatment of chronic diseases has been upgraded again, and the two sides will expand the existing cooperation in the field of chronic diseases to the field of atopic dermatitis diseases, and create the first one-stop online full-course management platform for atopic dermatitis for the public.
From the first exhibition to the first place
Xinkelai appeared with an "upgraded ID card"
After the debut of the Expo in 2021, thanks to the "spillover effect" of the Expo, the world's first targeting human anti-interleukin-5 (IL-5) monoclonal antibody Xinkelai (generic name: mepolizumab injection) was immediately approved in China for the rare disease of adult eosinophilic granulomatosis with polyangiitis (EGPA), and then the first batch of prescriptions officially landed.
This year's CIIE stage is not only a wonderful appearance of Xinkelai leapfrogging the first exhibition to the first place, but also shows the future prospects and great potential of the treatment of a series of inflammatory diseases caused by eosinophilia such as severe eosinophilic asthma (SEA), hypereosinophilic syndrome (HES) and chronic rhinosinusitis with nasal polyps (CRwNP), which has become the focus and hot topic of the industry.
Eosinophils are widely distributed in various target organs in the body and play an important role in both health and disease. It is a terminally differentiated, bone marrow-derived, granule-containing multifunctional leukocyte involved in the protective immune response of the host against parasitic infection and the immunopathophysiological process of allergic diseases. For human health, eosinophils are a "double-edged sword" that needs to be maintained within the normal range, and normal levels of eosinophils are beneficial to the human body, and too many are harmful. Excessive eosinophil proliferation can occur in a variety of diseases and can be a red flag, including chronic airway inflammation such as EGPA, asthma, and eosinophilic chronic obstructive pulmonary disease (COPD).
Interleukin-5 (IL-5) is a key cytokine in the regulation of eosinophils, and the therapeutic target of mepolizumab is IL-5, which binds to IL-5, blocks its binding to eosinophil surface receptors, inhibits the biological activity of eosinophils and continuously reduces their number to normal levels, thereby reducing eosinophil-mediated inflammation and tissue damage, and achieving the purpose of treating EGPA and a series of inflammatory diseases caused by eosinophilia.
Mepolizumab is a blockbuster product that GSK has high hopes for in the field of specialty drugs, and it shows great potential in the treatment and future applications of a range of inflammatory diseases associated with eosinophils. Qi Xin, vice president and general manager of GSK China, revealed, "In the future, we will continue to promote clinical research and expand indications, and also look forward to using the 'spillover effect' of CIIE to provide new treatment options for more Chinese patients affected by inflammatory diseases caused by eosinophilia." ”
"Old friends" bring new products and ideas
Inject new vitality into "Healthy China"
The "spillover effect" of the Expo is also reflected in the field of healthcare consumption. Herbalife participated in the 5th CIIE for the first time with a two-booth linkage, presenting its science-based high-quality nutritional products to Chinese consumers in one stop. Among them, Zhimanxing DHA algal oil gummy is "China's innovation, the world's premiere".
Guo Mu, President and Senior Vice President of Herbalife China, said: "With the official upgrade of 'Healthy China' to a national strategy and the public's increasing attention to their own nutrition and health, Chinese consumers are increasingly demanding personalized and high-quality nutritional products. In the future, I believe that the huge potential of China's nutrition and health market will continue to stimulate Herbalife's innovative vitality. ”
In the medical exhibition hall, multinational enterprises that have continuously participated in the Expo not only have larger booth areas and more exhibits, but also brought new ideas and strategies.
For example, Johnson & Johnson China's personal health care series has brought more than 40 world-leading innovative products, covering allergies, fever, pain, smoking cessation, eye care, wound care and other fields, spanning the two major categories of over-the-counter drugs and health food, relying on its comprehensive health solutions covering the whole life cycle, the whole population and the whole health link, showing the diversified trends and important values of personal health management to Chinese patients and the public.
Dai Kanglan, President of Johnson & Johnson China Personal Health Care, said that he was very pleased to be able to showcase health solutions from around the world at the Expo and inject new vitality into the development of China's personal health management business. "As a platform advocating openness and cooperation, CIIE not only provides us with an excellent vision of China, but also creates better opportunities for us to work with all parties to accelerate the introduction of innovative products and promote the development of personal health management."
Merck has been deeply engaged in the Chinese market for 89 years, and China has become an important strategic market and growth engine for Merck worldwide. Thanks to the open and shared international platform of CIIE, Merck China's business has also achieved considerable development in recent years. This time, Merck brings a new concept of "biofusion".
Bioconvergence combines cross-disciplinary disciplines such as biotechnology, digital technology and materials science to improve the efficiency of scientific research and promote product innovation and manufacturing capacity upgrading in related industries. Driven by strong policy support and strong market demand, biofusion has a strong growth momentum and broad prospects in the world and China.
"With the 'spillover effect' of CIIE, this year, Merck focuses on the new trend of 'biofusion' and shares revolutionary benefits and insights, which is highly in line with the key development tasks of China's "14th Five-Year Plan" for the development of the bioeconomy. "Merck will make full use of the unique advantages, expertise and global resources related to biofusion in its three businesses, and continue to work closely with China's local innovation ecosystem to jointly promote cross-field innovation in biofusion to improve people's well-being and help achieve the goal of 'Healthy China'." ”
In the past five years, CIIE has continued to take health as a key issue, continuously introducing new products, new technologies and new services, and earnestly seeking benefits for people's health from the material and technical levels. With the follow-up of policies to accelerate drug review and approval, the number of approved marketing of innovative drugs and innovative medical devices in 2021 reached a new high. The "birth" of more and more "babies" in the Expo shows the "acceleration" of China's innovation and provides opportunities for multinational companies.
Taking advantage of the "spillover effect" of the Expo, riding on national policies and the east wind of the Expo, the former exhibits have completed the "identity" change in China, and more innovative achievements and high-quality medical resources are serving Chinese patients and the public faster and better.
(Source: Pudong release)